Investigating how Pyk2 affects immune cells and vesicle release in aggressive brain tumors.
Official title: Pyk2 regulates extracellular vesicles release in GBM cells and modulates activation of tumor infiltrating myeloid cells
Funded at Universidad Central Del Caribe · NIH-10793667 · Data updated 2026-11-12
This study is looking at how a protein called Pyk2 affects the immune response in glioblastoma, a tough type of brain cancer, to find new ways to improve treatment for patients like you.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $381,843 |
| NIH project number | 1R15CA287203-01 |
| Project ID | NIH-10793667 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with non-cancerous brain conditions or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain cancer, and aims to understand the role of a protein called Pyk2 in the tumor's immune environment. By studying how Pyk2 influences the release of extracellular vesicles and the behavior of tumor-infiltrating myeloid cells, the research seeks to identify new molecular targets for improving GBM treatment. The approach involves analyzing tumor samples and cell cultures to assess the impact of Pyk2 on immune cell activation and tumor growth. Patients may benefit from insights that could lead to more effective therapies for GBM.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the immune response against glioblastoma, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in targeting immune cell interactions in tumors, suggesting that this approach could be effective in glioblastoma as well.
Where this research is happening
-
Universidad Central Del Caribe
Bayamon, United States Active
Researchers
- Principal investigator: Kucheryavykh, Lilia — Universidad Central Del Caribe
- Study coordinator: Kucheryavykh, Lilia
Related research
Other NIH-funded projects on the same topics.
-
Targeted breast cancer treatment using a natural product to block cancer cell survival
A patient-friendly look at a grant that supports testing a natural compound that may stop a tough type of breast cancer from thriving.
-
Ultracentrifuge for separating small molecules, compounds, and vesicles
A new ultracentrifuge will be bought for a shared core facility to speed up high-precision separation of tiny particles and molecules for multiple biomedical research projects.
-
Blocking Pyk2 to help immune therapy work better for glioblastoma
Seeing if stopping a protein called Pyk2 can make immune checkpoint drugs (like PD-L1 blockers) work better for people with glioblastoma.
-
Beta-amyloid build-up in the brain for Parkinson's disease
This research explores how a protein called amyloid beta, often linked to Alzheimer's, builds up in the brains of people with Parkinson's disease, especially when dementia develops.
-
Understanding how beta-amyloid builds up in the brain of Parkinson's disease patients
This study is looking at how a substance called amyloid beta builds up in the brains of people with Parkinson's disease as they start to experience dementia, and it aims to find out how this buildup happens and what role blood cells and inflammation play in the process.
-
Investigating how ergosterol peroxide can selectively inhibit aggressive breast cancer
This study is looking at how a natural compound from fungi, called ergosterol peroxide, can help fight triple-negative breast cancer by killing cancer cells without harming normal cells, with the hope of creating a new treatment option for patients facing this tough type of cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.